Acute liver injury leading to death in the setting of brentuximab vedotin monotherapy

Neeman, Jeremy; Friedman, Anthony; McKendrick, Joseph

doi:10.1080/10428194.2019.1579321

Cited by 4 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Overall, five cases due to amoxicillin-clavulanate induced liver injury receiving UDCA ( Chawla et al, 2000 ; Katsinelos et al, 2000 ; Studniarz et al, 2012 ; Ahmed et al, 2020 ) have been reported ( Table 1 ). Furthermore, three associated to androgenic anabolic steroid (AAS) ( Sánchez-Osorio et al, 2008 ; Krishnan et al, 2009 ; Stępień et al, 2015 ), three cases due to the combination of AAS and dietary supplements ( Singh et al, 1996 ; El Khoury et al, 2017 ; Abeles et al, 2020 ), three due to Centella asiatica ( Jorge and Jorge, 2005 ), two associated with immune check point inhibitors ( Kurokawa et al, 2019 ; Onishi et al, 2020 ), one reaction each due to terbinafine ( Agca et al, 2004 ), flutamide ( Cicognani et al, 1996 ), ibandronate ( Goossens et al, 2013 ), brentuximab vedotin ( Neeman et al, 2019 ), methimazole ( Gallelli et al, 2009 ), and Kratom that were treated with UDCA ( Fernandes et al, 2019 ).…”

Section: Resultsmentioning

confidence: 99%

“…Clinical improvement after UDCA treatment was observed in almost all amoxicillin-clavulanate cases (4 out of 5) but only 2 out of 6 cases due to AAS with or without dietary supplements. Among the other nine DILI reports, therapeutic response to UDCA was found to be positive in all except for one associated with brentuximab vedotin (Neeman et al, 2019) In addition, there was one case of vanishing bile duct syndrome due to amoxicillin-clavulanate (Smith et al, 2005) and another one due to a combination of haloperidol, prochlorperazine, amitriptyline and phenytoin (O'Brien et al, 1996). In both of these reports important improvement was observed after starting treatment with UDCA.…”

Section: Case Reports Dealing With Ursodeoxycholic Acid In the Drug-induced Liver Injury Treatment Or Preventionmentioning

confidence: 99%

See 2 more Smart Citations

Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Introduction: Treatment is generally not available for drug-induced liver injury (DILI) patients except in some specific circumstances. The management of DILI is based on the withdrawal of the responsible drug and monitoring the patients and only a few patients need to be referred to a transplant center. Some studies on the role of ursodeoxycholic acid (UDCA) in DILI have been published. The aim of this study was to perform a systematic review of the role of UDCA in the treatment and prevention of DILI.Methods: A search was undertaken in PubMed, with the key words ursodeoxycholic acid, drug-induced liver injury and hepatotoxicity following the PRISMA guidelines.Results: A total of 33 publications were identified: 25 case reports and 8 case series. In 18 of the 25 cases reports (22 patients), authors reported improvement of liver injury associated with UDCA therapy whereas 7 case reports did not show clinical or biochemical improvement after UDCA treatment. There were 4 studies evaluating the role of UDCA in the treatment of DILI, three prospective (one being a clinical trial) and one retrospective studies. Three studies observed liver profile improvements associated with UDCA. In addition, four studies evaluated UDCA in the prevention of DILI: one pilot study, two randomized clinical trials (RCT) and one retrospective study. Three of these studies observed a lower percentage of patients with an increase in transaminases in the groups that used UDCA for DILI prevention.Conclusion: According to available data UDCA seems to have some benefits in the treatment and prevention of DILI. However, the design of the published studies does not allow a firm conclusion to be drawn on the efficacy of UDCA in DILI. A well designed RCT to evaluate the role of UDCA in DILI is needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Case Reports Dealing With Ursodeoxycholic Acid In the Drug-induced Liver Injury Treatment Or Preventionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Additionally, brentuximab is associated with a similar hepatotoxicity profile as well as favourable outcomes in recent trials, including the AHOD1331 trial 4. While a single case of severe liver injury was reported after seven cycles of full dose brentuximab vedotin in 2019, the incidence of hepatoxicity was low, likely between 0.61% and 1.4% 21 23. Additionally, it has been successfully employed in several other cases of VBDS 17–20.…”

Section: Discussionmentioning

confidence: 96%

“…However, because of this patient’s known hepatic dysfunction, we also wanted to minimise the morbidity of hepatotoxicity while maximising agents with known activity treating cHL. Given its efficacy in cholestasis, we initially treated it with ursodeoxycholic acid 21 22. Despite starting with a similar steroid regimen to the study by Scalabrini et al , the tests performed on liver showed worse results 17.…”

Section: Discussionmentioning

confidence: 99%

Hodgkin lymphoma associated vanishing bile duct syndrome treated successfully with a brentuximab based regimen

Morgan,

Weishar,

Kwok

et al. 2023

BMJ Case Rep

View full text Add to dashboard Cite

We report a combination therapy to successfully treat a patient with Hodgkin’s lymphoma complicated by vanishing bile duct syndrome. Our patient was in his 20s and presented with jaundice, emesis, B symptoms and diffuse lymphadenopathy along with cholestatic liver injury prompting a liver biopsy, which revealed this diagnosis, after the exclusion of other aetiologies. Our treatment regimen incorporated brentuximab along with other more conventional agents which attempted to maximise therapeutic efficacy while minimising the consequences of hepatotoxicity on the treatment protocol. Although this patient’s treatment course was complicated because of neutropenic infections, the patient achieved a complete metabolic response and is now more than 1 year off therapy.

show abstract

Brentuximab vedotin

2019

Reactions Weekly

View full text Add to dashboard Cite

Acute liver injury leading to death in the setting of brentuximab vedotin monotherapy

Cited by 4 publications

References 4 publications

Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review

Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review

Hodgkin lymphoma associated vanishing bile duct syndrome treated successfully with a brentuximab based regimen

Brentuximab vedotin

Contact Info

Product

Resources

About